z-logo
open-access-imgOpen Access
The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review
Author(s) -
Seyedeh Alia Moosavian,
Thozhukat Sathyapalan,
Tannaz Jamialahmadi,
Amirhossein Sahebkar
Publication year - 2021
Publication title -
bioinorganic chemistry and applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.865
H-Index - 35
eISSN - 1565-3633
pISSN - 1687-479X
DOI - 10.1155/2021/4041415
Subject(s) - nonalcoholic fatty liver disease , disease , fatty liver , medicine , liver disease , nanomedicine , drug delivery , intensive care medicine , bioinformatics , nanotechnology , biology , nanoparticle , materials science
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that can lead to end-stage liver disease needing a liver transplant. Many pharmacological approaches are used to reduce the disease progression in NAFLD. However, current strategies remain ineffective to reverse the progression of NAFLD completely. Employing nanoparticles as a drug delivery system has demonstrated significant potential for improving the bioavailability of drugs in the treatment of NAFLD. Various types of nanoparticles are exploited in this regard for the management of NAFLD. In this review, we cover the current therapeutic approaches to manage NAFLD and provide a review of recent up-to-date advances in the uses of nanoparticles for the treatment of NAFLD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom